Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

BUY
$23.16 - $32.34 $321,970 - $449,590
13,902 New
13,902 $423,000
Q1 2019

May 02, 2019

SELL
$12.79 - $17.62 $11,702 - $16,122
-915 Closed
0 $0
Q4 2018

Feb 08, 2019

BUY
$11.39 - $27.13 $10,421 - $24,823
915 New
915 $12,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $835M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Pearl River Capital, LLC Portfolio

Follow Pearl River Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pearl River Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pearl River Capital, LLC with notifications on news.